The Goldman Sachs Group Forecasts Strong Price Appreciation for Biogen (NASDAQ:BIIB) Stock

Key Points

• Goldman Sachs raised its price target on Biogen to $238 (from $231) and kept a "buy" rating, implying roughly a 29% potential upside from the current share price.
• Biogen recently beat quarterly estimates with $1.99 EPS (vs. $1.61) and $2.28B revenue (vs. $2.21B), set FY‑2026 guidance of $15.25–$16.25 EPS (analysts average 15.77), but revenue was down 7.2% year‑over‑year and the consensus analyst rating remains a Hold with an average target of $211.81.

Biogen (NASDAQ:BIIB - Get Free Report) had its target price lifted by stock analysts at The Goldman Sachs Group from $231.00 to $238.00 in a research report issued to clients and investors on Friday,MarketScreener reports. The firm presently has a "buy" rating on the biotechnology company's stock. The Goldman Sachs Group's target price would suggest a potential upside of 29.08% from the stock's current price.

A number of other equities research analysts have also commented on the company. UBS Group upgraded Biogen from a "neutral" rating to a "buy" rating and upped their target price for the company from $185.00 to $225.00 in a research report on Wednesday. Truist Financial reduced their price target on shares of Biogen from $193.00 to $189.00 and set a "hold" rating for the company in a research report on Monday, April 13th. Royal Bank Of Canada lowered their price objective on Biogen from $233.00 to $213.00 and set an "outperform" rating on the stock in a report on Tuesday, April 7th. Argus upgraded Biogen to a "hold" rating in a report on Thursday, April 9th. Finally, Wells Fargo & Company increased their target price on shares of Biogen from $190.00 to $200.00 and gave the company an "equal weight" rating in a research report on Sunday, February 8th. Fourteen analysts have rated the stock with a Buy rating, thirteen have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of "Hold" and an average target price of $211.81.

Biogen Trading Down 1.9%

Shares of BIIB opened at $184.38 on Friday. The company has a 50 day simple moving average of $185.13 and a two-hundred day simple moving average of $175.03. Biogen has a 1 year low of $115.25 and a 1 year high of $202.41. The firm has a market cap of $27.06 billion, a P/E ratio of 20.93, a price-to-earnings-growth ratio of 2.51 and a beta of 0.16. The company has a debt-to-equity ratio of 0.34, a current ratio of 2.68 and a quick ratio of 2.03.

Biogen (NASDAQ:BIIB - Get Free Report) last released its quarterly earnings results on Friday, February 6th. The biotechnology company reported $1.99 earnings per share for the quarter, beating the consensus estimate of $1.61 by $0.38. The company had revenue of $2.28 billion for the quarter, compared to analyst estimates of $2.21 billion. Biogen had a return on equity of 12.64% and a net margin of 13.07%.Biogen's quarterly revenue was down 7.2% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $3.44 EPS. Biogen has set its FY 2026 guidance at 15.250-16.250 EPS. On average, equities analysts expect that Biogen will post 15.77 earnings per share for the current fiscal year.

Insider Transactions at Biogen

In other news, insider Priya Singhal sold 2,660 shares of Biogen stock in a transaction dated Monday, February 9th. The stock was sold at an average price of $199.83, for a total transaction of $531,547.80. Following the sale, the insider owned 8,043 shares in the company, valued at approximately $1,607,232.69. The trade was a 24.85% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 0.18% of the stock is owned by company insiders.

Institutional Trading of Biogen

A number of hedge funds have recently added to or reduced their stakes in BIIB. Convergence Investment Partners LLC purchased a new stake in Biogen in the 3rd quarter worth about $1,342,000. Caprock Group LLC acquired a new stake in shares of Biogen during the third quarter worth approximately $742,000. Leuthold Group LLC bought a new position in shares of Biogen in the 3rd quarter valued at approximately $3,294,000. Generali Investments Management Co LLC lifted its holdings in Biogen by 408.2% in the 3rd quarter. Generali Investments Management Co LLC now owns 9,970 shares of the biotechnology company's stock worth $1,397,000 after purchasing an additional 8,008 shares during the last quarter. Finally, CWM LLC boosted its position in Biogen by 36.4% during the third quarter. CWM LLC now owns 47,455 shares of the biotechnology company's stock worth $6,648,000 after purchasing an additional 12,673 shares during the period. 87.93% of the stock is owned by institutional investors and hedge funds.

More Biogen News

Here are the key news stories impacting Biogen this week:

• Positive Sentiment: Biogen struck a China deal to develop felzartamab as a domestically produced anti‑CD38 therapy for multiple myeloma — this expands its China footprint and could open a meaningful growth market. Biogen seeks Darzalex rivalry in China for multiple myeloma with felzartamab deal
• Positive Sentiment: UBS upgraded Biogen, and JPMorgan raised its price target to $185 (still a Neutral rating) — these moves provide some analyst validation for the story but stop short of a full buy case. UBS upgrades Biogen (BIIB) JPMorgan raises price target
• Neutral Sentiment: Q1 earnings preview pieces highlight that new products (Skyclarys, Zurzuvae) are driving growth but legacy MS sales face competitive pressure — outcome of Q1 will be a key catalyst and remains uncertain. Biogen Q1 Earnings: Can New Launches Offset Declining MS Franchise?
• Neutral Sentiment: Rothschild & Co Redburn issued EPS estimates and raised its price target to $180 while maintaining a Neutral rating — adds supply of modeled forecasts but not a bullish call. Rothschild & Co Redburn estimates and target
• Negative Sentiment: Short interest rose to ~4.41M shares as of April 15 (+15.4% vs. March 31), representing about 3.0% of float and a short‑interest ratio ~3.1 days — higher shorting can amplify downward pressure around weak news. (Note: an April 24 data point showing zero shares appears to be a reporting anomaly.)
• Negative Sentiment: Wolfe Research trimmed Q1 and Q2 EPS estimates (and trimmed Q2 guidance), signaling risk to near‑term earnings expectations and likely contributing to negative trading sentiment.

About Biogen

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer's disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company's marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.